Evonile Pharma (500672) Q4 25/26 earnings summary

Executive summary

• FY26 revenue from operations was 3,543.3 million and profit for the year was 931.8 million, compared with 3,562.7 million and 1,009.0 million in FY25.

• Q4 FY26 profit was 252.5 million versus 160.9 million in Q4 FY25; the quarter’s results are balancing figures derived from full-year audited results and nine-month figures.

Financial highlights

• Q4 revenue from operations was 905.5 million vs 859.0 million YoY; FY26 revenue was 3,543.3 million vs 3,562.7 million in FY25.

• FY26 total income was 3,931.0 million vs 3,982.3 million; other income was 387.7 million vs 419.6 million.

• FY26 profit before tax was 1,296.6 million vs 1,304.2 million; profit for the year was 931.8 million vs 1,009.0 million.

• FY26 basic and diluted EPS was 37.74 vs 40.87; Q4 EPS was 10.23 vs 6.52 in Q4 FY25.

Segment performance

• One operating segment, Pharmaceutical Business, with revenue generated in India.

• One customer accounted for traded-goods revenue above 10% of total: 1,461.7 million in FY26 vs 1,626.9 million in FY25.